Biohaven Ltd. (BHVN) Insider Trading Activity
NYSE$16.02
Market Cap
$1.64B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
59 of 877
Rank in Industry
42 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BHVN Insider Trading Activity
BHVN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $7,276,250 | 8 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| CHILDS JOHN W | director | 5 | $5.05M | 0 | $0 | $5.05M |
| Car Bruce | Chief Scientific Officer | 1 | $1.01M | 0 | $0 | $1.01M |
| Coric Vlad | Chief Executive Officer | 1 | $999,970 | 0 | $0 | $999,970 |
| Bailey Gregory | director | 1 | $220,966 | 0 | $0 | $220,966 |
About Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Insider Activity of Biohaven Ltd.
Over the last 12 months, insiders at Biohaven Ltd. have bought $7.28M and sold $0 worth of Biohaven Ltd. stock.
On average, over the past 5 years, insiders at Biohaven Ltd. have bought $23.17M and sold $27.65M worth of stock each year.
Highest buying activity among insiders over the last 12 months: CHILDS JOHN W (director) — $5.05M. Car Bruce (Chief Scientific Officer) — $1.01M. Coric Vlad (Chief Executive Officer) — $999,970.
The last purchase of 32,700 shares for transaction amount of $996,238 was made by CHILDS JOHN W (director) on 2025‑03‑04.
List of Insider Buy and Sell Transactions, Biohaven Ltd.
| 2025-03-04 | CHILDS JOHN W | director | 32,700 0.0315% | $30.47 | $996,238 | -30.61% | ||
| 2024-12-30 | CHILDS JOHN W | director | 29,000 0.0281% | $35.94 | $1.04M | -16.82% | ||
| 2024-10-02 | Coric Vlad | Chief Executive Officer | 21,052 0.0215% | $47.50 | $999,970 | -21.38% | ||
| 2024-10-02 | CHILDS JOHN W | director | 21,052 0.0215% | $47.50 | $999,970 | -21.38% | ||
| 2024-09-24 | Bailey Gregory | director | 5,000 0.0047% | $44.19 | $220,966 | -14.81% | ||
| 2024-07-18 | CHILDS JOHN W | director | 28,400 0.0218% | $35.67 | $1.01M | +10.99% | ||
| 2024-06-17 | Car Bruce | Chief Scientific Officer | 30,000 0.0217% | $33.58 | $1.01M | +15.46% | ||
| 2024-05-30 | CHILDS JOHN W | director | 28,000 0.0214% | $35.58 | $996,240 | +7.10% | ||
| 2024-05-13 | CHILDS JOHN W | director | 28,500 0.0215% | $35.17 | $1M | +11.81% | ||
| 2024-05-13 | Bailey Gregory | director | 15,000 0.011% | $34.19 | $512,877 | +11.81% | ||
| 2024-04-24 | Bailey Gregory | director | 25,503 0.0215% | $39.18 | $999,169 | -1.32% | ||
| 2024-04-22 | Coric Vlad | Chief Executive Officer | 121,951 0.1075% | $41.00 | $5M | -0.05% | ||
| 2024-04-22 | Bailey Gregory | director | 48,780 0.043% | $41.00 | $2M | -0.05% | ||
| 2024-04-22 | CHILDS JOHN W | director | 73,170 0.0645% | $41.00 | $3M | -0.05% | ||
| 2023-12-29 | Sale | Antonijevic Irina | director | 11,000 0.0099% | $41.79 | $459,663 | -0.12% | |
| 2023-10-05 | CHILDS JOHN W | director | 454,545 0.2149% | $22.00 | $10M | +61.12% | ||
| 2023-10-05 | Coric Vlad | Chief Executive Officer | 454,545 0.2149% | $22.00 | $10M | +61.12% | ||
| 2023-10-05 | Buten Matthew | Chief Financial Officer | 22,727 0.0107% | $22.00 | $499,994 | +61.12% | ||
| 2023-10-04 | Bailey Gregory | director | 17,817 0.0086% | $22.57 | $402,094 | +69.45% | ||
| 2023-08-30 | CHILDS JOHN W | director | 50,000 0.0198% | $18.44 | $922,180 | +106.32% |
Total: 184
*Gray background shows transactions not older than one year
Insider Historical Profitability
33.96%
| CHILDS JOHN W | director | 2320571 2.2726% | $37.18M | 21 | 2 | +50.25% |
| Bailey Gregory | director | 1620071 1.5866% | $25.95M | 9 | 22 | +28.96% |
| Coric Vlad | Chief Executive Officer | 861942 0.8441% | $13.81M | 8 | 8 | +21.13% |
| Car Bruce | Chief Scientific Officer | 30000 0.0294% | $480,600.00 | 1 | 0 | |
| Cha Albert | director | 1976818 1.9359% | $31.67M | 1 | 0 | |
| Doogan Declan | director | 870648 0.8526% | $13.95M | 0 | 31 | |
| Buten Matthew | Chief Financial Officer | 189380 0.1855% | $3.03M | 2 | 0 | +39.3% |
| PORTAGE BIOTECH INC. | 54494 0.0534% | $872,993.88 | 0 | 7 | ||
| GREGORY JULIA P | director | 25665 0.0251% | $411,153.30 | 1 | 3 | +17.49% |
| Engelhart James | Chief Financial Officer | 11196 0.011% | $179,359.92 | 2 | 9 | |
| Stock Elyse | Chief Medical Officer | 7467 0.0073% | $119,621.34 | 0 | 5 | |
| Clark George C. | VP, Chief Accounting Officer | 4065 0.004% | $65,121.30 | 0 | 3 | |
| Conway Charles | Chief Scientific Officer | 4000 0.0039% | $64,080.00 | 1 | 0 | |
| Gentile Kimberly | SVP, Clinical Operations | 3639 0.0036% | $58,296.78 | 0 | 11 | |
| Antonijevic Irina | director | 2535 0.0025% | $40,610.70 | 0 | 1 | |
| JONES WILLIAM A JR | CCO-Migraine & Common Disease | 1755 0.0017% | $28,115.10 | 0 | 1 | |
| AGUIAR ERIC | director | 1250 0.0012% | $20,025.00 | 0 | 7 | |
| Tilton John | Chief Commercial Officer | 770 0.0008% | $12,335.40 | 0 | 4 | |
| Berman Robert | Special Projects & Med Ovrsght | 341 0.0003% | $5,462.82 | 2 | 22 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$11,583,737 | 45 | 49.75% | $1.49B | |
$100,002,191 | 42 | 21.48% | $1.61B | |
$148,770,544 | 34 | 80.63% | $1.36B | |
$1,295,059 | 29 | 102.78% | $1.36B | |
$150,253,463 | 26 | -52.83% | $1.67B | |
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) | $95,404,562 | 18 | 33.96% | $1.64B |
$154,554,190 | 14 | 29.60% | $1.69B | |
$92,580,864 | 14 | -1.28% | $1.55B | |
$75,296,816 | 12 | 37.23% | $1.97B | |
$137,013,690 | 11 | 26.62% | $1.68B | |
$45,445,266 | 9 | -24.96% | $1.56B | |
$32,575,266 | 8 | 37.03% | $1.84B | |
$107,098,946 | 7 | 1.61% | $1.44B | |
$91,325,021 | 6 | 1.83% | $1.34B | |
$142,493,653 | 3 | 4.30% | $1.92B | |
$103,599,972 | 2 | -36.81% | $1.82B | |
$5,000,000 | 1 | -22.84% | $1.37B | |
$7,600,000 | 1 | -4.05% | $1.94B | |
$10,000,009 | 1 | 100.92% | $1.67B |
BHVN Institutional Investors: Active Positions
| Increased Positions | 149 | +56.23% | 10M | +11.97% |
| Decreased Positions | 114 | -43.02% | 8M | -9.07% |
| New Positions | 40 | New | 2M | New |
| Sold Out Positions | 44 | Sold Out | 3M | Sold Out |
| Total Postitions | 300 | +13.21% | 89M | +2.89% |
BHVN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $192,263.00 | 8.25% | 8.41M | +628,211 | +8.07% | 2024-12-31 |
| Blackrock, Inc. | $170,983.00 | 7.34% | 7.48M | -184,333 | -2.4% | 2025-03-31 |
| Janus Henderson Group Plc | $159,548.00 | 6.85% | 6.98M | +756,032 | +12.14% | 2024-12-31 |
| Stifel Financial Corp | $149,880.00 | 6.43% | 6.56M | +50,052 | +0.77% | 2024-12-31 |
| Suvretta Capital Management, Llc | $128,423.00 | 5.51% | 5.62M | +421,052 | +8.1% | 2024-12-31 |
| Farallon Capital Management Llc | $101,184.00 | 4.34% | 4.43M | +785,578 | +21.57% | 2024-12-31 |
| State Street Corp | $80,260.00 | 3.44% | 3.51M | +255,842 | +7.86% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $77,969.00 | 3.35% | 3.41M | -26,335 | -0.77% | 2024-12-31 |
| Fmr Llc | $48,311.00 | 2.07% | 2.11M | +273,185 | +14.84% | 2024-12-31 |
| Bellevue Group Ag | $46,633.00 | 2% | 2.04M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.